Results of nanoparticle-encapsulated curcumin on HIV-gp120-associated neuropathic ache induced by the P2X3 receptor in dorsal root ganglia.
Mind Res Bull. 2017 Oct;135:53-61
Authors: Zhao S, Yang J, Han X, Gong Y, Rao S, Wu B, Yi Z, Zou L, Jia T, Li L, Yuan H, Shi L, Zhang C, Gao Y, Li G, Liu S, Xu H, Liu H, Liang S
HIV-1 envelope glycoprotein (Glycoprotein 120, gp120) can straight stimulate main sensory afferent neurons and trigger power neuropathic ache. The P2X3 receptor within the dorsal root ganglia (DRG) is related to the transmission of neuropathic ache. Curcumin remoted from the herb Curcuma rhizome has anti-inflammatory and anti-tumor results. The water solubility, concentrating on and bioavailability of curcumin might be improved by nanoparticle encapsulation. On this research, we sought to discover the results of nanoparticle-encapsulated curcumin (nano curcumin) on HIV-gp120-induced neuropathic ache mediated by the P2X3 receptor in DRG neurons. The outcomes confirmed that mechanical and thermal hyperalgesia in rats handled with gp120 had been elevated in comparison with these within the management group. The expression ranges of P2X3 mRNA and protein in rats handled with gp120 had been larger than these within the management group. Nano curcumin therapy decreased mechanical hyperalgesia and thermal hyperalgesia and upregulated the expression ranges of P2X3 mRNA and protein in rats handled with gp120. Nano curcumin therapy additionally decreased the ERK1/2 phosphorylation ranges in gp120-treated rat DRG. As well as, P2X3 agonist ?,?-methylene ATP (?,?-meATP)-induced currents in DRG neurons cultured with gp120 considerably decreased after co-treatment with nano curcumin. Subsequently, nano curcumin therapy could inhibit P2X3 activation, lower the sensitizing DRG main afferents and relieve mechanical hyperalgesia and thermal hyperalgesia in gp120-treated rats.
PMID: 28962965 [PubMed – indexed for MEDLINE]